AGBL2 and rheumatoid arthritis: Taken together, when applying the high cut-off, 53 early RA patients were triple positive for anti-CCP2 IgG, anti-CCP2 IgA and anti-CCP3.1; 36 patients were double positive for anti-CCP2 IgG and anti-CCP3.1; 7 patients were solely positive for anti-CCP2 IgG and 8 patients solely for anti-CCP3.1.